S1 Biopharma Supports FDA Advisory Committee’s Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder

NEW YORK, June 5, 2015 /PRNewswire/ — Yesterday’s FDA Advisory Committee recommendation for the approval of flibanserin was a landmark step for women’s health, addressing the important unmet medical need for women living with hypoactive sexual desire disorder, or HSDD.…